08.05.2012 - Satisfied investors again hand out money to UK-biotech Oxford Nanopore. Almost all of the newly raised €39m comes from existing funders.
Oxford – British next generation sequencing specialist Oxford Nanopore Technologies Ltd has announced that its recent fundraising round has been successful. All in all, €39.0m (£31.4m) will lubricate the biotech’s plans to boost its operational standing. CEO Gordon Sanghera wants to spend the money on different fronts: „This round of funding will support a range of corporate development activities including the development of our commercial infrastructure and the expansion of our manufacturing function. We will also continue to maintain our leadership position in nanopore innovation through maintenance and expansion of our broad intellectual property portfolio."
Almost all the money comes from existing investors via private placements of ordinary shares. Oxford Nanopore summed up that the total amount raised in the company’s life since its inception as a University of Oxford spin-off in 2005 is about €130.2m. The up-and-coming high-tech shack has developed a rapid and cheap new sequencing technology based on nanopores to directly and electronically detect and analyse single molecules. Since the first public demonstration of the technology in mid-February friends and foes alike early await its direct to customer commercialisation in the manifestations of the GridION platform and the MinION device in the second half of 2012. Currently, competitors such as Roche/IBM are just in research stage.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more